ScreenerHero

GUBRA Gubra A/S

CPH · DK · Healthcare · Biotechnology · gubra.dk
292.60DKK-1.08%Mkt Cap: 699.74M $P/E: —

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Pre…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap699.74M USD
Enterprise Value610.68M USD
Revenue (TTM)39.48M USD
Gross Profit372.39M USD
Net Income (TTM)246.23M USD
Revenue/Share16.59 DKK
Last Price292.60 DKK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees330
CountryDK
SectorHealthcare
IndustryBiotechnology
ISINDK0062266474
Valuation
P/E (Trailing)—
P/E (Forward)171.72
PEG—
EV/EBITDA-21.88
EV/Revenue15.47
P/S18.10
P/B4.69
EPS (TTM)-11.10
EPS (Forward)1.74
52W Range
287.202% of range557.50
52W High557.50 DKK
52W Low287.20 DKK
Profitability
Gross Margin96.96%
Oper. Margin-97.28%
EBITDA Margin-70.71%
Profit Margin64.11%
ROE147.53%
ROA128.09%
Growth
Revenue Growth-94.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF249.41M USD
CapEx (TTM)2.79M USD
FCF Margin-661.76%
FCF Yield-37.33%
Net Debt-104.09M USD
Net Debt/EBITDA3.73
Balance Sheet
Debt/Equity0.09
Current Ratio11.42
Quick Ratio10.74
Book Value/Sh63.67 DKK
Cash/Share54.88 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 DKK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 30, 2025
Pay Date—
Analyst Consensus
Rating—
Target (Mean)501.00 DKK
Upside (mean)+71.2%
Target Range403.00 DKK – 600.00 DKK
403.00+71.2% to mean600.00
# Analysts3
Ownership
Shares Out.16.42M
Float6.81M
Insiders58.23%
Institutions11.81%
Technical
SMA 50351.00 (-16.6%)
SMA 200372.32 (-21.4%)
Beta0.31
S&P 52W Chg14.58%
Avg Vol (30d)31.60K
Avg Vol (10d)29.31K
Technical Indicators
RSI (14)37.7
MACD-14.3279
MACD Signal-15.1468
MACD Hist.+0.8190
BB Upper327.44 DKK
BB Middle305.37 DKK
BB Lower283.30 DKK
BB Width14.46%
ATR (14)14.88 DKK
Vol Ratio (20d)1.11x